A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

This study has been terminated.

(The study was terminated for business reasons and not due to any safety or efficacy concerns related to omarigliptin.)

Sponsor:

Information provided by (Responsible Party):

Merck Sharp & Dohme Corp.

ClinicalTrials.gov Identifier:

NCT01703208

First received: October 5, 2012

Last updated: May 19, 2016

Last verified: May 2016

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Study Completion Date:	May 2016
Primary Completion Date:	May 2016 (Final data collection date for primary outcome measure)